These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28856009)

  • 1. The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled Trial.
    Clark WF; Huang SH; Garg AX; Gallo K; House AA; Moist L; Weir MA; Sontrop JM
    Can J Kidney Health Dis; 2017; 4():2054358117725106. PubMed ID: 28856009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial.
    Clark WF; Sontrop JM; Huang SH; Gallo K; Moist L; House AA; Cuerden MS; Weir MA; Bagga A; Brimble S; Burke A; Muirhead N; Pandeya S; Garg AX
    JAMA; 2018 May; 319(18):1870-1879. PubMed ID: 29801012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.
    Sontrop JM; Huang SH; Garg AX; Moist L; House AA; Gallo K; Clark WF
    BMJ Open; 2015 Nov; 5(11):e008634. PubMed ID: 26603245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Coaching to Increase Water Intake in CKD.
    Ivanova MD; Gozhenko AI; Crestanello T; Ivanov DD
    Ann Nutr Metab; 2020; 76 Suppl 1():69-70. PubMed ID: 33780940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial.
    Clark WF; Sontrop JM; Huang SH; Gallo K; Moist L; House AA; Weir MA; Garg AX
    BMJ Open; 2013 Dec; 3(12):e003666. PubMed ID: 24362012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
    Amro OW; Paulus JK; Noubary F; Perrone RD
    Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
    El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
    BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease-1: Study Protocol for a Multicenter Clinical Trial.
    Weir MA; Walsh M; Cuerden MS; Sontrop JM; Chambers LC; Garg AX
    Can J Kidney Health Dis; 2018; 5():2054358118813088. PubMed ID: 30619615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial.
    Peralta CA; McClure LA; Scherzer R; Odden MC; White CL; Shlipak M; Benavente O; Pergola P
    Circulation; 2016 Feb; 133(6):584-91. PubMed ID: 26762524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
    McCallum W; Tighiouart H; Ku E; Salem D; Sarnak MJ
    Am J Kidney Dis; 2020 Jan; 75(1):21-29. PubMed ID: 31303349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effects of Intensive Low-Salt Diet Education on Deterioration of Glomerular Filtration Rate among Non-Diabetic Hypertensive Patients with Chronic Kidney Disease.
    Ahn SY; Kim DK; Park JH; Shin SJ; Lee SH; Choi BS; Lim CS; Lee A; Jung H; Chin HJ
    Kidney Blood Press Res; 2019; 44(5):1101-1114. PubMed ID: 31533093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
    Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
    Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Water Intake in Chronic Kidney Disease: Why? Safe? Possible?
    Clark WF; Sontrop JM; Moist L; Huang SH
    Ann Nutr Metab; 2015; 66 Suppl 3():18-21. PubMed ID: 26088042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pragmatic Cluster Randomized Trial of an Electronic Clinical Decision Support System to Improve Chronic Kidney Disease Management in Primary Care: Design, Rationale, and Implementation Experience.
    Khoong EC; Karliner L; Lo L; Stebbins M; Robinson A; Pathak S; Santoyo-Olsson J; Scherzer R; Peralta CA
    JMIR Res Protoc; 2019 Jun; 8(6):e14022. PubMed ID: 31199334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 2 Clinical Decision Support Strategies on Chronic Kidney Disease Outcomes in Primary Care: A Cluster Randomized Trial.
    Carroll JK; Pulver G; Dickinson LM; Pace WD; Vassalotti JA; Kimminau KS; Manning BK; Staton EW; Fox CH
    JAMA Netw Open; 2018 Oct; 1(6):e183377. PubMed ID: 30646261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.